Takeda Initiates Phase III Lung Cancer Trial in Four Asian Countries

Takeda Pharmaceutical and Millennium: The Takeda Oncology Company have announced that Takeda Bio Development Center has initiated a Phase III clinical trial in Japan, Hong Kong, South Korea and Taiwan, evaluating motesanib in combination with chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Equities